Results

1–5 of 5 results for voretigene neparvovec

Safety and Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 8 Years and 9 Years
Stephen R. Russell, MD
Annual Meeting Talks
2024
A Multicenter Post-Authorization Safety Study of Patients Treated With Voretigene Neparvovec-rzyl Gene Therapy in the United States: Interim Analysis at 3 Years
Aaron Nagiel, MD, PhD
Annual Meeting Talks
2024
Year 1 Time to Mobility Test Completion in a Voretigene Neparvovec-rzyl Trial in Subjects With RPE65 Mutation–Associated Inherited Retinal Disease
Julia A. Haller, MD
On Demand Cases, Courses, and Papers
2018
3-Year Update for the Phase 3 Voretigene Neparvovec-rzyl Study in Biallelic RPE65 Mutation-Associated Inherited Retinal Disease
Stephen R. Russell, MD
Annual Meeting Talks
2018
3-Year Update for the Phase 3 Voretigene Neparvovecrzyl Study in Biallelic RPE65 Mutation–Associated Inherited Retinal Disease
Stephen R. Russell, MD
Updates from the Field
2018